Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.
Explore how machine learning is revolutionising interstitial lung disease management, enhancing early diagnosis, treatment, ...
MyChesCo on MSN
FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults ...
Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...
Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...
The protein on human cells that tick-borne encephalitis virus (TBEV) uses for infection has now been identified—a major step toward understanding how TBEV causes neurological disease and for ...
Among adults with obesity who lost weight after following a low-calorie diet, weight-loss maintenance with exercise was ...
GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDTCompany ParticipantsJulie Brown - CFO & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback